Introduction
============

Hepatocellular carcinoma (HCC) is a serious health problem, which accounts for more than 700,000 new cases worldwide annually.[@b1-ott-11-7883],[@b2-ott-11-7883] HCC is the second leading cause of cancer-related death in many countries and regions.[@b3-ott-11-7883] The Barcelona Clinic Liver Cancer (BCLC) staging system has been widely accepted as a treatment guideline that comprehensively considers tumor burden, hepatic function, and performance status of patients with HCC.[@b4-ott-11-7883],[@b5-ott-11-7883] Sorafenib is a multikinase inhibitor that targets raf kinase, which participates in the proliferation of tumor cells, and vascular endothelial growth factor (VEGF) receptor-2, VEGF receptor-3, and platelet-derived growth factor receptor, which contribute to angiogenesis of tumor cells. In clinical practice, according to the current guidelines, including the BCLC staging classification, sorafenib is the standard treatment modality for patients with advanced HCC in many countries. In previous studies, sorafenib was proved to prolong overall survival by 2.3--2.8 months and improve the response rate by 2.0%--3.3%, compared to placebo.[@b6-ott-11-7883],[@b7-ott-11-7883] However, because of the comprehensive consideration of limited efficacy, adverse events, and high cost, the clinical benefits of sorafenib were still unsatisfying.

In the last decade, epirubicin-, cisplatin-, interferon-, or 5-fluorouracil-based transcatheter hepatic arterial infusion chemotherapy (HAIC) was widely used for patients with BCLC stage C HCCs in Asian countries. HAIC was suggested as a promising treatment as it can inhibit tumor growth through antiangiogenic mechanisms with less toxicity and fewer systemic side effects than the maximum tolerated dose therapy. Several studies have reported the clinical effectiveness of HAIC for BCLC stage C HCCs, with response rates ranging from 20.8% to 52%, and the median survival time in complete and partial responders is approximately 40 and 17 months, respectively.[@b8-ott-11-7883]--[@b10-ott-11-7883] Some previous studies comparing the clinical efficacy of HAIC with that of sorafenib suggested that HAIC was superior to sorafenib for patients with BCLC stage C HCCs.[@b8-ott-11-7883],[@b12-ott-11-7883]--[@b14-ott-11-7883] However, some other studies reported conflicting results.[@b10-ott-11-7883],[@b11-ott-11-7883],[@b15-ott-11-7883]

To the best of our knowledge, no meta-analysis studies have been performed to compare the clinical benefits and safety of HAIC with those of sorafenib in the treatment of patients with BCLC stage C HCCs. In this study, we designed a meta-analysis to compare comprehensively the efficacy and safety of HAIC with those of sorafenib for BCLC stage C HCCs. We hope that the comparison of these treatments could help stratify the benefits of treatment choices for patients with HCC.

Methods
=======

Search strategy
---------------

In this meta-analysis, Medline, PubMed, Embase, Cochrane Library, and Chinese databases (Wanfang Data and China National Knowledge Infrastructure) were searched for studies comparing the clinical efficacy and safety of HAIC with those of sorafenib in the treatment of patients with BCLC stage C HCCs from January 2007 to June 2017. The study search used the following MeSH search headings: "hepatocellular carcinoma" or "primary liver cancer", "BCLC stage C", "transcatheter", "hepatic arterial infusion chemotherapy", and "sorafenib". A limit was set on clinical studies that were designed to compare the clinical effectiveness and adverse events of HAIC with those of sorafenib in BCLC stage C HCCs. There was no language restriction in this search.

Inclusion criteria of published trials
--------------------------------------

To be considered as eligible in this meta-analysis, the enrolled studies were required to have comparative data on clinical efficacy (overall survival rate \[OSR\], tumor response rate, disease control rate \[DCR\]) and adverse events of HAIC and sorafenib in patients with BCLC stage C HCCs. The inclusion criteria were as follows: 1) trial design: the trials must be designed as clinical studies with comparative data on clinical effectiveness and adverse events of HAIC and sorafenib for BCLC stage C HCCs; 2) clear document indications for use of HAIC and sorafenib; 3) treatment design: HAIC vs sorafenib; 4) characteristics of patients: the studies were required to have relatively integrated basic characteristics of enrolled patients, such as average age, percentage of male, Child--Pugh class, tumor size, portal vein tumor thrombosis (PVTT), and virus infection; 5) time of publication: from January 2007 to June 2017; and 6) study results: at least one item of results on OSR, tumor response rate, DCR, or adverse event was applicable.

Reviews without abstracts, original data, editorials, expert opinions, letters, case reports, and studies lacking control groups were excluded from the analysis.

Evaluation strategy
-------------------

Data extraction was independently conducted by two reviewers using the standardized methods, with any disagreements being settled by discussion of the respective study data and adjudicated by an experienced reviewer. From each study, the following data were abstracted: data for publication details (name of the first author and year of publication) and study characteristics (study design, age, gender of patients, study design, tumor size, tumor number, Child--Pugh class, OSR, tumor response rate, incidence of adverse events, etc.).

Statistical analysis
--------------------

Statistical analyses were performed on dichotomous outcomes, and standard meta-analytical techniques were used in this study. Pooled ORs with 95% CIs were calculated using either the fixed-effects model or the random-effects model. For each meta-analysis, the *χ*^2^ and *I*^2^ statistics were first calculated to assess the heterogeneity of the included studies. *P*\<0.1 and *I*^2^\>50% were considered significant. For *P*\<0.1 and *I*^2^\>50%, the random-effects model was used; otherwise, data were assessed using the fixed-effects model. The risk of publication bias in this study was assessed by visual inspection of the symmetry of the funnel plot. All statistical analyses were performed using Review Manager (version 5.3) from the Cochrane Collaboration. The significance of the pooled ORs was assessed by the *Z*-test. *P*\<0.05 was considered significant.

Results
=======

Search results
--------------

This study found a total of 86 potentially relevant studies. On the basis of the inclusion and exclusion criteria of this study, 10 retrospective cohort studies comparing the clinical efficacy and adverse events of HAIC with those of sorafenib for the treatment of BCLC stage C HCCs were finally included.[@b8-ott-11-7883]--[@b17-ott-11-7883] The flowchart of the search strategy for included studies is shown in [Figure 1](#f1-ott-11-7883){ref-type="fig"}. A total of 1,264 patients were included in the study, of whom 505 patients underwent sorafenib treatment and 759 patients underwent HAIC treatment. The basic characteristics, OSR, tumor response rate, and DCR of patients in enrolled trials are summarized in [Tables 1](#t1-ott-11-7883){ref-type="table"} and [2](#t2-ott-11-7883){ref-type="table"}. The quality of the included studies was assessed using the Cochrane Collaboration's tool.

Meta-analysis results
=====================

OSR
---

Six, four, and four studies reported the comparative data for OSR at 1, 2, and 3 years, respectively. From the results of tests for heterogeneity between trials (*χ*^2^~1-year~ =7.16, *P*~1-year~ =0.21, *I*^2^~1-year~ =30%; *χ*^2^~2-year~ =1.15, *P*~2-year~ =0.77, *I*^2^~2-year~ =0%; *χ*^2^~3-year~ =1.70, *P*~3-year~ =0.64, *I*^2^~3-year~ =0%), the fixed-effects model was used to pool the results in the analysis of the effects of OSR. Compared to sorafenib, the data and forest plots of our study showed that HAIC was associated with significantly higher 1-, 2-, and 3-year OSR in the treatment of patients with BCLC stage C HCC (OR 1.88, 95% CI~1-year~: \[1.27--2.78\], *P*~1-year~=0.002; OR 2.15, 95% CI~2-year~: \[1.06--4.37\], *P*~2-year~=0.03; OR 7.90, 95% CI3-year: \[2.12--29.42\], *P*~3-year~=0.002) ([Figure 2](#f2-ott-11-7883){ref-type="fig"} and [Table 3](#t3-ott-11-7883){ref-type="table"}).

Tumor response to therapy
-------------------------

Nine, nine, nine, nine, and ten studies reported the comparative data for tumor response rate in terms of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), and objective response rate (ORR), respectively. From the results of tests for heterogeneity between trials (*χ*^2^~CR~ =7.76, *P*~CR~ =0.26, *I*^2^~CR~ =23%; *χ*^2^~PR~ =14.95, *P*~PR~ =0.06, *I*^2^~PR~ =46%; *χ*^2^~SD~ =29.72, *P*~SD~ =0.0002, *I*^2^~SD~ =73%; *χ*^2^~PD~ =34.62, *P*~PD~ ≤0.0001, *I*^2^~PD~ =38%; *χ*^2^~OR~ =12.73, *P*~OR~ =0.08, *I*^2^~OR~ =45%), either the random-effects model or the fixed-effects model was used to pool the results in the analysis of the effects of CR, PR, SD, PD, and OR. The data and forest plots of our study revealed that HAIC was associated with obviously better CR, PR, and OR than sorafenib (OR 3.90, 95% CI~CR~: \[1.89--8.03\], *P*~CR~ =0.0002; OR 3.47, 95% CI~PR~: \[2.31--5.24\], *P*~PR~ \<0.00001; OR 3.02, 95% CI~OR~: \[2.05--4.45\], *P*~OR~ \<0.0001). There was no statistically significant difference between HAIC and sorafenib in stable SD and PD (OR 0.86, 95% CI~SD~: \[0.51--1.45\], *P*~SD~ =0.56; OR 0.62, 95% CI~PD~: \[0.35--1.11\], *P*~PD~ =0.11) ([Figure 3](#f3-ott-11-7883){ref-type="fig"} and [Table 3](#t3-ott-11-7883){ref-type="table"}).

DCR
---

Six studies reported the comparative data on DCR of HAIC and sorafenib for patients with BCLC stage C HCC. From the results of tests for heterogeneity between trials (*χ*^2^~DCR~ =26.21, *P*~DCR~ ≤0.0001, *I*^2^~DCR~ =83%), the random-effects model was used to pool the results in the analysis of the effects of DCR. The data and forest plot of our study showed no statistically significant difference in DCR between HAIC and sorafenib (OR 1.84, 95% CI~DCR~: \[0.78--4.36\], *P*~DCR~ =0.16) ([Figure 4](#f4-ott-11-7883){ref-type="fig"} and [Table 3](#t3-ott-11-7883){ref-type="table"}).

Serious adverse events
----------------------

In this meta-analysis, the incidence of serious adverse events (SAEs) of HAIC and sorafenib in the treatment of patients with BCLC stage C HCC was analyzed and compared. Here, the SAEs were defined as Common Terminology Criteria for Adverse Events grade 3/4 adverse events or adverse events that lead to discontinuation of treatment with HAIC or sorafenib. Seven studies reported the comparative data on SAEs of HAIC and sorafenib for patients with BCLC stage C HCC. From the results of tests for heterogeneity between trials (*χ*^2^~SAE~ =30.89, *P*~SAE~ ≤0.0001, *I*^2^~SAE~ =81%), the random-effects model was used to pool the results in the analysis of the effects of SAEs. The data and forest plot of our study showed no statistically significant difference in SAEs between HAIC and sorafenib (OR 0.53, 95% CI~SAE~: \[0.14--1.92\], *P*~SAE~ =0.33) ([Figure 5](#f5-ott-11-7883){ref-type="fig"} and [Table 3](#t3-ott-11-7883){ref-type="table"}).

Assessment of publication bias
------------------------------

In this study, the risk of publication bias was assessed by visual inspection of the symmetry level of funnel plot. The fixed-effects model was used to pool the results in the analysis of the effects of CR, PR, OR, and 1-, 2-, and 3-year OSRs. The results of our meta-analysis revealed that the symmetry level of the funnel plots was high. This suggested that there was no serious publication bias in the trials included in this study ([Figure 6](#f6-ott-11-7883){ref-type="fig"}).

Discussion
==========

The BCLC staging classification is one of the most widely used guidelines for the clinical treatment of HCC in many countries. According to the BCLC staging classification, BCLC stage C HCC is suggested as the advanced-stage HCC, and sorafenib is considered as the primary treatment option for HCCs of that stage. However, because of the adverse effects, moderate efficacy, and high cost of sorafenib, its application is limited. Thus, the clinical benefits of sorafenib are still not satisfactory. To improve the prognosis of patients with advanced HCC, alternative treatment strategies are being investigated. In the recent years, HAIC was proved as an effective and safe therapy for advanced HCC. Previous studies had reported that HAIC was associated with better efficacy than sorafenib for patients with advanced HCCs.[@b8-ott-11-7883],[@b12-ott-11-7883]--[@b14-ott-11-7883] However, some other studies had reported conflicting results.[@b10-ott-11-7883],[@b11-ott-11-7883],[@b15-ott-11-7883] Meta-analysis is a method that combines data from all eligible studies, and has the advantages of reducing random error, obtaining more precise estimates, and defining the effect of clinical interventions more precisely.[@b18-ott-11-7883],[@b19-ott-11-7883] Hence, meta-analysis is an eligible method to resolve such conflicts. In this study, the OSR, tumor response rate, and the incidence of SAEs were analyzed and compared. The results of this study showed that HAIC was associated with significantly better OSR and tumor response rate in comparison with sorafenib. This indicated that HAIC was superior to sorafenib in the treatment of patients with advanced HCCs.

In this meta-analysis, epirubicin-, cisplatin-, or 5-fluorouracil-based HAIC was performed by the transcatheter method, and the chemotherapeutic agent was delivered through the hepatic arterial infusion chemoport. From previous studies and our clinical practice, we found that the mechanisms by which HAIC affects HCCs might include the inhibition of angiogenesis, stimulation of immunity, and direct inhibition of tumor cell proliferation.[@b8-ott-11-7883],[@b14-ott-11-7883],[@b20-ott-11-7883]--[@b22-ott-11-7883] Inhibition of angiogenesis is the most important mechanism. During HAIC treatment, the angiogenesis of tumor cells can be inhibited by direct destruction and inhibition of proliferation of endothelial cells. Further, the expression levels of endogenous antiangiogenic factors and endogenous angiogenic factors were reported to be upregulated and downregulated, respectively.[@b23-ott-11-7883],[@b24-ott-11-7883] Recently, the reduction in endothelial progenitor cell mobilization and stimulation of immunity were also investigated as mechanisms of HAIC for HCC.[@b23-ott-11-7883],[@b24-ott-11-7883]

PVTT is an important cause of tumor spread, portal hypertension, and deterioration of liver function, leading to variceal rupture, intractable ascites, and hepatic encephalopathy. Patients with advanced HCC and PVTT were associated with poor prognosis, with a median survival time ranging from 2.7 to 4 months. As the first-line treatment option suggested by the BCLC staging system, sorafenib can prolong the survival of patients with PVTT from 6.5 to 8 months.[@b25-ott-11-7883],[@b26-ott-11-7883] However, the survival benefits and treatment responses of sorafenib in patients with advanced HCCs with PVTT were modest. Thus, the availability of sorafenib is limited. In recent years, surgical resection or transarterial chemoembolization in selected patients, HAIC, external radiation, I^125^ seed implantation, radioembolization, and combination therapies have been performed as alternative treatment options for patients with advanced HCCs with PVTT.[@b25-ott-11-7883]--[@b27-ott-11-7883] Compared to sorafenib, HAIC was proved to be associated with more favorable clinical efficacy in terms of overall survival and tumor response in the treatment of patients with PVTT. In previous studies in which HAIC was performed for HCC with PVTT, the ORR and DCR ranged from 33% to 52.6% and 47.1% to 77%, respectively.[@b27-ott-11-7883]--[@b30-ott-11-7883] Two randomized controlled trials (RCTs) showed that ORR was 2%--3%, and the DCR was 57.3%--73%.[@b6-ott-11-7883],[@b7-ott-11-7883] Hence, from the data of previous studies and our study, we found that the ORR of HAIC was significantly higher than that of sorafenib, whereas the DCR of the two treatments appeared to be identical. In this study, the meta-analysis data showed that HAIC was associated with significantly better 1-, 2-, and 3-year OS rates and CR, PR, and ORR in comparison with sorafenib. This indicated that the results of our meta-analysis study were reliable.

This study is the first meta-analysis designed to comprehensively compare the clinical efficacy and safety of HAIC with those of sorafenib in the treatment of patients with HCCs of BCLC stage C. In this study, the OSR, tumor response rate, DCR, and the incidence of SAEs were compared and analyzed. The risk of publication bias in the included studies was assessed by the visual inspection of the symmetry level of the funnel plot.[@b31-ott-11-7883],[@b32-ott-11-7883] The results of our study showed that the level of symmetry of the funnel plot was high. This suggested that there was no serious publication bias in the trials included in this meta-analysis. Thus, we can see that the studies included in the meta-analysis are strong evidence to support our results.

Finally, the potential limitations of this study must be mentioned. First, there were limited available and applicable RCTs comparing the effectiveness and adverse event of HAIC and sorafenib for the treatment of advanced HCCs in the last several years. However, although a meta-analysis has traditionally been applied and is best confined to RCTs, meta-analytical techniques using non-RCTs might be a valid method in clinical settings in which either the number or the sample size of the RCTs is insufficient.[@b33-ott-11-7883] In the future, more RCTs should be conducted to provide further evidence. Second, because all included studies in this meta-analysis were from Asian countries, data bias caused by the source of patients might be present. More high-quality RCTs from other continents and countries are needed to provide more data for future research.

Conclusion
==========

Our meta-analysis showed that HAIC was associated with better clinical efficacy and reliable safety in comparison with sorafenib for patients with BCLC stage C HCCs. Therefore, HAIC can be considered as an alternative treatment option for advanced HCCs.
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![The flowchart of the search strategy for study inclusion.\
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![HAIC vs sorafenib for BCLC stage C HCCs in terms of overall survival rates.\
**Notes:** (**A**) Meta-analysis of 1-year results. (**B**) Meta-analysis of 2-year results. (**C**) Meta-analysis of 3-year results.\
**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma.](ott-11-7883Fig2){#f2-ott-11-7883}

###### 

HAIC vs sorafenib for BCLC stage C HCCs in terms of tumor response rates.

**Notes:** (**A**) Meta-analysis of CR results. (**B**) Meta-analysis of PR results. (**C**) Meta-analysis of SD results. (**D**) Meta-analysis of PD results. (**E**) Meta-analysis of ORR results.

**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; CR, complete response; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.
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![HAIC vs sorafenib for BCLC stage C HCCs in terms of DCR.\
**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; DCR, disease control rate; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma.](ott-11-7883Fig4){#f4-ott-11-7883}

![HAIC vs sorafenib for BCLC stage C HCCs in terms of SAE.\
**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma; SAE, serious adverse event.](ott-11-7883Fig5){#f5-ott-11-7883}

![Funnel plots in the analysis of the effects of OSR and tumor response rate.\
**Notes:** (**A**) Funnel plot of 1-year OSR. (**B**) Funnel plot of 2-year OSR. (**C**) Funnel plot of 3-year OSR. (**D**) Funnel plot of CR rate. (**E**) Funnel plot of PR rate. (**F**) Funnel plot of ORR.\
**Abbreviations:** CR, complete response; OSR, overall survival rate; ORR, objective response rate; PR, partial response.](ott-11-7883Fig6){#f6-ott-11-7883}

###### 

Baseline characteristics of the included trials

  Study (year)                                 Country   Design   Treatment   No of pts       Age (years)     Sex (M/F)       Tumor size (cm)   Tumor number (solitary/multiple)   Child--Pugh class (A/B/C)   Virus infection (HBV/HCV)   PVTT (%)    Extrahepatic metastasis (%)
  -------------------------------------------- --------- -------- ----------- --------------- --------------- --------------- ----------------- ---------------------------------- --------------------------- --------------------------- ----------- -----------------------------
                                                                                                                                                                                                                                                       
  Yang et al (2017)[@b8-ott-11-7883]           Korea     RCS      Sorafenib   53              58.0±9.2        39/14           9.2±5.1           17/36                              34/19/0                     43/4                        53 (100)    35 (66.0)
                                                         HAIC     54          54.4±11.0       50/4            12.5±4.6        8/46              25/29/0                            44/6                        54 (100)                    28 (51.9)   
  Terashima et al (2017)[@b9-ott-11-7883]      Japan     RCS      Sorafenib   51              69 (median)     45/6            NA                NA                                 51/0/0                      16/24                       NA          25 (49.0)
                                                         HAIC     139         69 (median)     111/28          NA              NA                139/0/0                            36/75                       NA                          24 (17.3)   
  Hatooka et al (2016)[@b10-ott-11-7883]       Japan     RCS      Sorafenib   58              70 (50--88)     43/15           3.2 (0.5--19)     24/34                              NA                          13/40                       58 (100)    6 (10.3)
                                                         HAIC     65          67 (46--84)     59/6            4.0 (1.5--14)   17/48             NA                                 15/43                       65 (100)                    34 (52.3)   
  Fukubayashi et al (2015)[@b11-ott-11-7883]   Japan     RCS      Sorafenib   72              68.9±9.84       51/21           NA                NA                                 61/11/0                     15/36                       21 (29.2)   33 (45.8)
                                                         HAIC     128         65.5±9.32       113/15          NA              NA                79/49/0                            33/77                       64 (50.0)                   33 (25.8)   
  Kawaoka et al (2015)[@b12-ott-11-7883]       Japan     RCS      Sorafenib   41              69 (30--81)     29/12           4.0 (1.0--19)     NA                                 NA                          15/24                       14 (34.1)   14 (34.1)
                                                         HAIC     136         67 (30--85)     123/13          4.5 (1.0--18)   NA                NA                                 33/75                       92 (67.6)                   92 (67.6)   
  Kondo et al (2015)[@b13-ott-11-7883]         Japan     RCS      Sorafenib   83              70 (37--88)     74/9            NA                NA                                 78/5/0                      15/52                       20 (24.0)   NA
                                                         HAIC     44          71 (54--84)     32/12           NA              NA                31/13/0                            1/33                        24 (54.5)                   NA          
  Song et al (2015)[@b14-ott-11-7883]          Korea     RCS      Sorafenib   60              55.8±9.0        44/16           NA                NA                                 47/13/0                     41/5                        60 (100)    21 (35)
                                                         HAIC     50          54.3±9.9        38/12           NA              NA                45/5/0                             44/2                        50 (100)                    12 (24)     
  Shiozawa et al (2014)[@b17-ott-11-7883]      Japan     RCS      Sorafenib   47              69.4±8.2        43/4            NA                NA                                 39/8/0                      8/27                        NA          8 (17.0)
                                                         HAIC     77          67.3±6.8        64/13           NA              NA                49/26/2                            14/47                       NA                          3 (3.8)     
  Jeong et al (2012)[@b16-ott-11-7883]         Korea     RCS      Sorafenib   20              59.5 (49--75)   11/9            3.0±0.9           NA                                 NA                          13/NA                       NA          10 (50)
                                                         HAIC     21          51 (33--75)     21/0            3.4±0.2         NA                NA                                 18/NA                       NA                          7 (33)      
  Hiramine et al (2011)[@b15-ott-11-7883]      Japan     RCS      Sorafenib   20              69.6 (44--83)   17/3            NA                NA                                 14/18/0                     5/10                        NA          6 (30)
                                                         HAIC     45          69.6 (47--84)   32/13           NA              NA                26/24/0                            11/2                        NA                          5 (25)      

**Note:** Data presented in Age and Tumor size as mean±SD and median (range A to B).

**Abbreviations:** F, female; HAIC, hepatic arterial infusion chemotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male; NA, not available; pts, patients; PVTT, portal vein tumor thrombosis; RCS, retrospective cohort study.

###### 

The prognosis of patients reported in the included trials

  Study (year)                                 Treatment   No of pts       1-year OSR      2-year OSR    3-year OSR    5-year OSR     CR               PR               SD               PD               ORR             DCR
  -------------------------------------------- ----------- --------------- --------------- ------------- ------------- -------------- ---------------- ---------------- ---------------- ---------------- --------------- ---------------
                                                                                                                                                                                                                          
  Yang et al (2017)[@b8-ott-11-7883]           Sorafenib   53              5.6% (3/53)     3.8% (2/53)   0% (0/53)     0% (0/53)      0% (0/41)        0% (0/41)        22% (9/41)       78% (32/41)      0% (0/41)       22% (9/41)
  HAIC                                         54          22.2% (12/54)   7.4% (4/54)     3.7% (2/54)   1.9% (1/54)   0% (0/54)      7% (4/54)        39% (21/54)      54% (29/54)      7% (4/54)        46% (25/54)     
  Terashima et al (2017)[@b9-ott-11-7883]      Sorafenib   51              4% (2/51)       0% (0/51)     0% (0/51)     0% (0/51)      0% (0/51)        6% (3/51)        45% (23/51)      45% (23/51)      5.9% (3/51)     51% (26/51)
  HAIC                                         139         15% (21/139)    4% (5/139)      2% (3/139)    1% (2/139)    9% (12/139)    27% (37/139)     32% (45/139)     29% (41/139)     35% (49/139)     68% (94/139)    
  Hatooka et al (2016)[@b10-ott-11-7883]       Sorafenib   58              NA              NA            NA            NA             2% (1.2/58)      4% (2.3/58)      60% (35/58)      27% (16/58)      6% (3.5/58)     NA
  HAIC                                         65          NA              NA              NA            NA            0% (0/65)      12% (21/65)      54% (35/65)      27% (17/65)      12% (7.8/65)     NA              
  Fukubayashi et al (2015)[@b11-ott-11-7883]   Sorafenib   72              NA              NA            NA            NA             4.2% (3/72)      11.1% (8/72)     59.7% (43/72)    25% (18/72)      15.3% (11/72)   NA
  HAIC                                         128         NA              NA              NA            NA            3.9% (5/128)   22.7% (29/128)   41.4% (53/128)   32% (41/128)     26.6% (34/128)   NA              
  Kawaoka et al (2015)[@b12-ott-11-7883]       Sorafenib   41              NA              NA            NA            NA             2.4% (1/41)      2.4% (1/41)      43.9% (18/41)    41.5% (17/41)    4.8% (2/41)     NA
  HAIC                                         136         NA              NA              NA            NA            5.9% (8/136)   25% (34/136)     40% (55/136)     21.3% (29/136)   30.9% (42/136)   NA              
  Kondo et al (2015)[@b13-ott-11-7883]         Sorafenib   83              42% (35/83)     17% (14/83)   0% (0/83)     NA             3.6% (3/83)      13.2% (11/83)    36.1% (30/83)    39.7% (33/83)    16.9% (14/83)   53.0% (44/83)
  HAIC                                         44          46% (20/44)     24% (11/44)     15% (7/44)    NA            6.8% (3/44)    11.3% (5/44)     16.0% (7/44)     59.1% (26/44)    18.1% (8/44)     34.1% (15/44)   
  Song et al (2015)[@b14-ott-11-7883]          Sorafenib   60              8.3% (5/60)     1.7% (1/60)   1.7% (1/60)   NA             0% (0/60)        13.3% (8/60)     31.7% (19/60)    55.0% (33/60)    13.3% (8/60)    45.0% (27/60)
  HAIC                                         50          2.4% (12/50)    8.0% (4/50)     8.0% (4/50)   NA            2% (1/50)      22% (11/50)      66% (33/50)      10.0% (5/50)     24.0% (12/50)    90.0% (45/50)   
  Shiozawa et al (2014)[@b17-ott-11-7883]      Sorafenib   47              38.2% (18/47)   NA            NA            NA             NA               NA               NA               NA               NA              NA
  HAIC                                         77          47% (36/77)     NA              NA            NA            NA             NA               NA               NA               NA               NA              
  Jeong et al (2012)[@b16-ott-11-7883]         Sorafenib   20              32.5% (7/20)    NA            NA            NA             0% (0/20)        10% (2/20)       25% (5/20)       65% (13/20)      NA              35% (7/20)
  HAIC                                         21          38.1% (8/21)    NA              NA            NA            0% (0/21)      19% (4/21)       23.8% (5/21)     57.1% (12/21)    NA               38.1% (8/21)    
  Hiramine et al (2011)[@b15-ott-11-7883]      Sorafenib   20              NA              NA            NA            NA             0% (0/20)        0% (0/20)        65% (13/20)      35% (7/20)       0% (0/20)       65% (13/20)
  HAIC                                         45          NA              NA              NA            NA            4.4% (2/45)    17.8% (8/45)     46.7% (21/45)    31.1% (14/45)    22.2% (10/45)    68.8% (31/45)   

**Abbreviations:** CR, complete response; DCR, disease control rate; HAIC, hepatic arterial infusion chemotherapy; NA, not available; ORR, objective response rate; OSR, overall survival rate; PD, progressive disease; PR, partial response; pts, patients; SD, stable disease.

###### 

Summary of the results in this meta-analysis

  Variables                    No of studies furnishing data   Results of HAIC and sorafenib   OR (95% CI)   *Z* (*Z*-test)       *P*-value   
  ---------------------------- ------------------------------- ------------------------------- ------------- -------------------- ----------- -----------
                                                                                                                                              
  **Clinical efficacy**                                                                                                                       
  Overall survival rate                                                                                                                       
   1-year                      6                               28.3%                           22.2%         1.88 (1.27--2.78)    3.16        0.002
   2-year                      4                               8.3%                            6.8%          2.15 (1.06--4.37)    2.13        0.03
   3-year                      4                               5.5%                            0.4%          7.90 (2.12--29.42)   3.08        0.002
  Tumor response rate                                                                                                                         
   CR                          9                               7.1%                            1.7%          3.90 (1.89--8.03)    3.68        0.0002
   PR                          9                               22.4%                           7.8%          3.47 (2.31--5.24)    5.95        \<0.00001
   SD                          9                               40.3%                           43.7%         0.86 (0.51--1.45)    0.58        0.56
   PD                          9                               31.3%                           43.0%         0.62 (0.35--1.11)    1.61        0.11
   ORR                         8                               25.2%                           9.8%          3.02 (2.05--4.45)    5.6         \<0.00001
  DCR                          6                               61.7%                           45.8%         1.84 (0.78--4.36)    1.39        0.16
  **Serious adverse events**   7                               13.1%                           20.4%         0.53 (0.14--1.92)    0.97        0.33

**Abbreviations:** CR, complete response; DCR, disease control rate; HAIC, hepatic arterial infusion chemotherapy; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.

[^1]: These authors contributed equally to this work
